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Abstract Small molecule permeability through cellular
membranes is critical to a better understanding of phar-
macodynamics and the drug discovery endeavor. Such
permeability may be estimated as a function of the free
energy change of barrier crossing by invoking the barrier
domain model, which posits that permeation is limited by
passage through a single ‘‘barrier domain’’ and assumes
diffusivity differences among compounds of similar
structure are negligible. Inspired by the work of Rezai and
co-workers (JACS 128:14073–14080, 2006), we estimate
this free energy change as the difference in implicit sol-
vation free energies in chloroform and water, but extend
their model to include solute conformational affects. Using
a set of eleven structurally diverse FDA approved com-
pounds and a set of thirteen congeneric molecules, we
show that the solvation free energies are dominated by the
global minima, which allows solute conformational distri-
butions to be effectively neglected. For the set of tested
compounds, the best correlation with experiment is
obtained when the implicit chloroform global minimum is
used to evaluate the solvation free energy difference.
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Introduction
The ability to cross a lipid bilayer is an essential character
that all drugs must posses. For example, a compound that
readily diffuses through the intestinal enterocyte boundary
is far more likely to be administered orally than a com-
pound that does not. Topically administered drugs, a
mainstay in dermatology, must often pass through several
epidermal layers and their associated membranes [1].
Likewise, pulmonary administered compounds, such as
those used in the treatment of Cystic Fibrosis [2], must
cross the alveolar epithelium and capillary endothelium
membranes before entering systematic circulation. Gener-
ally, with the exception of those targeting blood-borne
elements, all drugs must cross capillary membranes before
exiting systematic circulation and reaching their cellular
target, regardless of the administration route [3]. Even
drugs targeting blood platelets must pass through a cellular
membrane [3].
Experimental methods of measuring in vitro small
molecule membrane permeability commonly include the
cell based Caco-2 assay [4] and the artiﬁcial membrane
based PAMPA [5] assays. Caco-2 assays utilize a cell line
derived from human colon carcinoma, have characteristics
that resemble intestinal epithelial cells, including intercel-
lular junctions and transport proteins, and can yield per-
meabilities with good correlation to human oral drug
absorption [6]. Parallel Artiﬁcial Membrane Permeability
Assays (PAMPA), on the other hand, are a lower-cost,
higher-throughput alternative that utilize an artiﬁcial
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solved in an organic solvent, embedded in a porous ﬁlter.
As PAMPA lack intercellular junctions and active trans-
porters, permeability is exclusively passive. Despite the
difference in cell and artiﬁcial membrane based assays,
correlation between the two can be good [7].
Computational methods of predicting small molecule
membrane permeability are fundamentally important in
drug lead generation and optimization and are an actively
evolving area of methodological development. For exam-
ple, compound permeability estimates allow one to select a
compound library subset for docking, or to determine an
appropriate lead optimization strategy. While experimental
permeability measurements are ideal, they are often too
slow or expensive to ﬁlter the *10
4–10
6 compounds typ-
ical of a docking screen, and they require that a lead series
be synthesized before assay. Alternatively, computational
models can be rapid, often correlate well with experiment,
and range from the detailed and expensive molecular
dynamics (MD) methods [8, 9], to the less accurate but
inexpensive knowledge-based quantitative structural per-
meability relationship (QSPR) methods [10].
In2006,theJacobsongrouppublishedresultsfromaunique
physics-basedmethod,intermediateindetailbetweentheMD
and QSPR methods [11] that is loosely based on the homog-
enous solubility model of passive membrane permeability,
P ¼ð D=dÞKp. The permeability is P, (cm/s), the diffusion
coefﬁcient is D,( c m
2/s), the membrane thickness is d, (cm),
andKpisthe unitless partitioncoefﬁcientofthedrugbetween
bulkwaterandthemembrane,whichistakenasahomogenous
low-dielectric slab. By invoking the barrier domain model
[12], which posits that permeation is limited by passage
through a single ‘‘barrier domain,’’ and assuming diffusivity
differences are small, the model determines permeability as a
functionofthefreeenergychangeofbarriercrossing.Thefree
energy change of barrier crossing is estimated by the differ-
ence in implicit solvent chloroform and water solvation free
energies, evaluated using a single member of the conforma-
tional ensemble found at the global minimum in the chloro-
form solvent. The choice of implicit solvent, while not
necessarily the most accurate, captures the fundamental
dielectric character of the membrane and water phases but
incurs signiﬁcantly less computational cost than an all-atom
method. Consequently, the use of implicit solvent offers a
unique balance between accurate, high-cost, low throughput
all-atom methods, and less accurate, lower-cost higher
throughput methods.Whilethe modelworkedwellfora set of
cyclic peptides [11], performance deteriorated for two small
sets of drugs [11, 13]. This led us to explore whether a more
rigorous treatment of conformational distributions would
improve accuracy and how sensitive the method is to subtle
structural differences characteristic of lead optimization.
In this work, we investigate the affects of using a more
rigorous conformational distribution treatment by com-
paring three different conﬁguration integral approxima-
tions. We also expanded their study to include a set of
simple benzene congeners to determine how sensitive the
model is to subtle changes that might be proposed during
lead optimization. Moreover, we compare the performance
of each approximation to those of QikProp, a fast, easy to
use, knowledge-based pharmacokinetic property predictor
available from Schro ¨dinger [14]. In all cases, predictions
are compared to PAMPA data.
Methods and theory
Relating the homogenous solubility and barrier domain
models of membrane permeability
The barrier domain model of membrane permeability ratio-
nalizes treatment of structurally anisotropic membranes as
isotropic homogenous slabs. The barrier domain model,
w h i c hi sc o n s i s t e n tw i t hb o t he x p e r i m e n t[ 12] and computa-
tion [8, 9], posits that for polar compounds, permeability is
limited by passage through the highly ordered membrane
region immediately behind the acyl-chain head group link-
ages.Inthisregion,solubilityislowduetotheapolarcharacter
oftheacyl-hydrocarbonchain,anddiffusivityislowduetothe
ordered structure of the chains. Both characteristics give rise
to high permeability resistance, making passage through this
region rate limiting. The free energy change associated with
barrier crossing is then given by the difference in free energy
of the ensemble of conformations accessible at the hydrated
head groups, which constitute the membrane-water interface,
andthoseaccessibleatthe transitionstate intheorderedacyl-
chain membrane region. In this way, the homogenous solu-
bility model of passive membrane permeability is similar to
transition state theory, i.e. P ¼ð D=dÞe DG=RT where DGi s
the free energy of barrier crossing, and the diffusivity pre-
factormaybeassumedtoroughlycancelacrosssetsofsimilar
compounds. In this work, as in the work reported by the Jac-
obson group, the free energy barrier is estimated as the dif-
ference in chloroform and aqueous solvation freeenergies. In
the next section, we develop a statistical thermodynamic
expression for this free energy change, which leads to three
approximations.
Statistical thermodynamic formulation
If differences in intra-membrane diffusivity are neglected,
according to the homogenous solubility diffusion and
barrier domain models, the logged permeability of one
molecule relative to another is,
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b
2:3
DDG ð1Þ
where b = (RT)
-1, with R the universal gas constant and T
the temperature. The calculated quantity, DG, is the
difference in solvation free energies of a molecule
dissolved in water and in the membrane. Using an
implicit chloroform solvent to model the membrane,
implicit water to model an aqueous solution, and
assuming the difference in volume between the
chloroform and aqueous solutions is negligibly small, DG
is given,
e bDG ¼
R
e bðUðxÞþWCHCl3ðxÞÞdx
R
e bðUðxÞþWH2OðxÞÞdx
ð2Þ
U(x) is the potential energy of the ligand in a conformation
given by its coordinates x. WH2OðxÞ is the aqueous solva-
tion free energy, or solvation potential of mean force [15],
when the ligand is held in a conformation x; a similar
deﬁnition holds for WCHCl3ðxÞ. The solvation free energies
are further decomposed into electrostatic contributions that
arise from the difference in free energies of charging the
ligand in the solvent and gas phases, respectively, and a
non-polar contribution that results from creating a solute
sized cavity in the solvent [16].
While the conﬁguration integrals in Eq. 2 are evaluated
over all possible ligand conformations, the Boltzmann
factors in each are largest for conformations with low
potential and solvation free energies. Consequently, by
increasing the extent of conformational sampling around
the global minimum, each integral can be approximated
with increasing accuracy. Three approximations are dis-
cussed. The ﬁrst, which we denote ‘‘the single-state
approximation,’’ is consistent with the calculations repor-
ted by the Jacobson group [11, 13]. In the single-state
approximation, it’s assumed that the global minimum
conformation in chloroform dominates both integrals. This
assumption implies that the conformation that resides at the
global minimum in chloroform is the same conformation
that resides at the global minimum in water. If the global
minimum in chloroform is designated, xCHCl3, then apply-
ing the single-state approximation to Eq. 2 yields,
DG ¼ WCHCl3 xCHCl3 ðÞ   WH2O xCHCl3 ðÞ ð 3Þ
In the second, which we denote ‘‘the two-state
approximation,’’ it is assumed that the global minimum
in each solvent dominates their respective integrals. If the
global minimum in water is designated xH2O, and the global
minimum in chloroform is designated as above, then
applying the two-state approximation to Eq. 2 gives,
DG ¼ U xCHCl3 ðÞ þ WCHCl3 xCHCl3 ðÞ   U xH2O ðÞ
  WH2O xH2O ðÞ ð 4Þ
Finally, in the third approximation, which we denote
‘‘the predominate-states approximation,’’ we assume that
conformations in addition to the global minima contribute
signiﬁcantly to each integral. Predominate states methods
are well known, and have been used successfully to study
the thermodynamics of ligand binding in host–guest
systems [17] and proteins [18]. Characteristically, the
methods decompose the conﬁguration integral into a sum
of local conﬁguration integrals, each centered on a
minimum energy conformation enumerated during a
conformation search. The conﬁguration integrals are
evaluated by normal mode analysis in either bond-angle-
torsion (BAT) coordinates [19] or in the rigid-rotor-
harmonic oscillator coordinate system (RRHO) [20, 21].
In this work, the RRHO system is used. The RRHO
separates the ‘‘internal’’ normal coordinate vibrations from
the ‘‘external’’ translations and rotations, which leads to
rotational momentum free energy contributions and, along
with the predominate states approximation, allows an
approximation to Eq. 2 to be written,
e bDG ¼
P
i
ðIa;iIb;iIc;iÞ
1=2 R
Vi
e bðUðrÞþWCHCl3ðrÞÞdr
P
j
ðIa;jIb;jIc;jÞ
1=2 R
Vj
e bðUðrÞþWH2OðrÞÞdr
ð5Þ
Ia,i Ib,i Ic,i are the principal moments of inertia of the ith
conformation, similar deﬁnitions hold for Ia,j Ib,j Ic,j.T h er
coordinates are the 3L-6 internal coordinates of the ligand,
where L is the number of ligand atoms. Each integral is
evaluated using Monte Carlo importance sampling,
following the ‘‘mode integration,’’ or MINTA approach
[20]. Taking the chloroform integrals, for example,
Z
Vi
e bðUðrÞþWCHCl3ðrÞÞdr ¼
e bðUðrÞþWCHCl3ðrÞÞ
piðrÞ
  
Vi
ð6Þ
where the terms enclosed in hi denote an average over the
distribution pi(r) contained in the volume element Vi. The
average is numerically approximated by randomly
sampling M solute conformations from the multivariate
Gaussian produced by normal mode analysis in the RRHO
coordinate system,
e bðUðrÞþWCHCl3ðrÞÞ
piðrÞ
  
Vi
 
1
M
X M
k¼1
e bðUðrkÞþWCHCl3ðrkÞÞ
piðrkÞ
ð7Þ
Similar deﬁnitions and procedures exist for the integrals
evaluated in water.
Small molecule test set
We performed our calculations on two sets of small mol-
ecules. The ﬁrst, which we denote the ‘‘FDA set,’’ is a
structurally diverse set of eleven weakly basic FDA
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123approved compounds whose ‘‘intrinsic’’ permeabilities, i.e.
permeabilities if all molecules were in their uncharged
form, were estimated by ﬁtting PAMPA data using the
pKflux
a method [7]. These eleven compounds are the same
as those used by the Jacobson group and allow a direct
comparison of our results [13]. These compound structures
are shown in Fig. 1.
To test the sensitivity of the calculations to the subtle
structural changes typical of lead optimization, we selected a
congeneric series of thirteen phenol and aniline derivatives,
which we denote the ‘‘congeneric set,’’ whose structures are
shown in Fig. 2. The ‘‘effective’’ permeabilities of these
compounds were measured by PAMPA [22]. Unlike intrinsic
permeability, effective permeability does not correct for the
presenceofchargedspeciesifthecompoundisacidicorbasic.
Assuming that only the uncharged species can cross the lipid
bilayer, effective permeabilities will always be less than
intrinsic permeabilities for titratable compounds. This can be
problematic in some instances. For example, two compounds
with very different pKa values can have very different effec-
tive permeabilities, despite having identical intrinsic perme-
abilities.Theanilineandphenolderivativesinthecongeneric
set have roughly the same proportion of uncharged species in
solution, however, the discrepancy between effective and
intrinsic permeabilities is not expected to have gross, erro-
neouseffectsontherelativepermeabilitycalculationsthatwe
describe.Forbothcompoundsets,allofthecalculationswere
performedwiththecompoundsintheirneutral,oruncharged,
states.
Computational methods
Monte Carlo (MC) conformational searches were carried
out using the MC Multiple Minimum program in v9.7 of
MacroModel within the Schro ¨dinger molecular modeling
suite [23]. Initial coordinates for the FDA set were obtained
from PDB ﬁles found at the drug databank (drugbank.ca).
Initial coordinates for the congeneric set were constructed
using the modeling facilities in maestro [24]. A 10,000 step
MC conformational search was performed using a gen-
eralized Born surface area (GBSA) solvent model, taking
parameters that match either water or chloroform. As in the
previously described works [11, 13], solute force ﬁeld
parameters were described using the 2005 OPLS parameter
set, which has been enhanced by Schro ¨dinger to provide a
larger coverage of organic functionality. MC was per-
formed by randomly varying between 1 and 5 torsions,
over a range of angles between 0 and 180, producing a
trial conformation. Trial conformations were minimized for
1,000 steps using Polak-Ribiere conjugate gradient mini-
mization. Minimized trial structures were retained if their
energy was less than 12 kcal mol
-1 above the current
global minimum, and if the distance separating any one
heavy atom (or hydroxyl or thiol hydrogen atom) on the
minimized trial conformation was greater than 0.5 A ˚ from
the position of the equivalent heavy atom (or hydroxyl or
thiol hydrogen atom) on each of the previously retained
conformations after a rigid-body least squares ﬁtting. MC
trial conformations were initiated from the least-used
structure, a strategy that has previously been shown to
increase the convergence rate.
Successfully determining the global minimum in a given
solvent requires exhaustively searching the conformational
landscape, an effort that can be frustrated if large energetic
barriers separate adjacent regions. To ensure adequate
conformational sampling, seven additional MC searches
were performed for each solute in each solvent, and the
global minima were extracted from the combined search
N
O
N
O
N
N N
N
O
Alfentanil
O
OH
N
H
Alprenol
O
H 2N
O
OH
H
N
Atenolol
HN
N
S
NH
HN
N
Cimetidine
N
S
N
O
O
O
OCH3
Diltiazem
H3 CO
O
OH
N
H
Metoprolol
OH
HO
OH
H
N
Nadolol
HN
O
OH
H
N O
OH
N
H
Proranolol
HO
OH
OH
H
N
Terbutaline Pindolol
C
N
N OCH3
OCH3
Verapamil
Fig. 1 Structures and names of the 11 compounds in the FDA set
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123results after removing redundant conformations. The ﬁrst
four additional searches were initiated from conformations
at energy intervals of 0 to 1, 1 to 2, 2 to 3 and 3 to
5 kcal mol
-1 above the global minimum determined in the
ﬁrst search. The remaining 3 searches were initiated from
conformations with energies greater than 5 kcal mol
-1
above the global minimum of the ﬁrst search. When pos-
sible, each conformation was separated by a least
1 kcal mol
-1 from the others. This is similar to multi-copy
molecular dynamics simulations, which have been shown
to increase conformational sampling in the protein crambin
[25] and produce greater statistical precision in simulations
of the RN24 peptide [26]. In a conformational search,
adequate convergence occurs when additional searching
does not contribute new, unique conformations. Conver-
gence may be monitored by plotting the total number of
conformations as a function of the number of MC searches
performed, which was done for the compounds in the FDA
set (supplementary Fig. 1); as fewer new conformations are
found, these plots should asymptotically approach a ﬁxed
value, indicating convergence. As compounds in the conge-
neric set have fewer rotatable bonds, we only performed a
singleconformationalsearch,asoutlinedabove,andassumed
that it was sufﬁcient for convergence. In all conformational
searches, symmetrically equivalent conformations were
retained and no electrostatic cutoffs were used.
Following the MC searches, each conformation was re-
minimized using 1,500 steps of truncated Newton
conjugate gradient minimization to determine the global
minimum. For the single-state approximation, the terms in
Eq. 3 were evaluated by calculating the solvation PMF
with GBSA models of water and chloroform using the
global minimum conformation determined in chloroform.
The change in free energy for the two-state approxi-
mation was evaluated similarly, but the global minimum
determined in water was also used and the free energy
difference was evaluated according to Eq. 4. For both the
single and two-state approximations, energy evaluations
were carried out using the ‘‘current energy’’ function in
MacroModel, which is accessible through Schro ¨dinger’s
Maestro interface or the command line. In all energy
evaluations, no electrostatic cutoffs were used.
MINTA [20, 23] was used to evaluate each unique
conformation after the results of all eight MC conforma-
tional searches were combined. Importance sampling
integration was carried out according to Eq. 7 for the ten
normal coordinates with the lowest vibrational frequencies,
while the analytical expression of the conﬁguration integral
over the remaining modes was determined. The integration
volume, Vi, for the numerically integrated modes was
chosen as the smaller of ±3r or ±3A ˚, in order to reduce
large inaccuracies that may arise if the potential energy
along one or more of the numerically integrated modes
exhibits extensive anharmonicity [20]. Additionally, the
choice decreases the likelihood that the integration vol-
umes of adjacent states will overlap, resulting in double
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Fig. 2 Structures and names of the 13 compounds in the congeneric set
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123counting [20]. As in the MC conformational search, a
combination of the Schro ¨dinger-extended 2005 OPLS force
ﬁeld and GBSA implicit solvent were used to describe the
energy surface. The principal moments of inertia for each
minimum-energy conformation were determined in a post-
processing step within Matlab [27] by diagonalizing the
associated unit-mass inertial tensor. Unit masses were used
to be consistent with the unit-mass Hessian, which MINTA
employs when determining the sampling distributions [27].
QikProp v3.2 was used to predict Caco-2 permeabilities
[14]. As QikProp does not predict PAMPA permeabilities,
only Caco-2 permeabilities are reported. QikProp perme-
ability calculations are conformationally invariant, and for
both the FDA and congeneric set, starting conformations
were used without minimization.
Results and discussion
The FDA set
The logarithm of the experimentally determined perme-
abilities are plotted against the corresponding DG values
determined using the single-state, two-state, and predomi-
nate-states approximations in Fig. 3a, b and c, respectively.
The QSPR results are shown in Fig. 3d. The single-state
approximation has an R
2 of 0.75, the two-state approxi-
mation an R
2 of 0.68, the predominant-states approxima-
tion an R
2 of 0.71, and the QSPR method predictions have
an R
2 of 0.75. The single-state approximation results are
very slightly better than the values previously reported by
Kalyanaraman and Jacobson [13], who carried out a single
conformational search, which may not have converged to
the true global minimum. For example, plotting the linear-
correlation coefﬁcient as a function of the number of
independent MC searches combined to ﬁnd the global
minimum conformation (supplementary Fig. 2) shows that
after the 5th conformational search, a new global minimum
is found, and the linear correlation improves.
The relative contributions to the free energy of those
conformations near the global minimum bears on the cal-
culated outcomes. To estimate this quantity, we calculated
the fraction of free energy due to conformations within
1.00 kcal mol
-1 of the global minimum, as well as the
factional contribution of just the global minimum. Repor-
ted in Table 1, these values indicate that despite the hun-
dreds to thousands of conformations in the ensemble
(supplementary Fig. 1), the global minima constitute 97 to
99% of the total free energy, while conformations within
1.00 kcal mol
-1 comprise greater than 99% of the total.
This shows that sampling additional contributions beyond
the global minima does little to alter the value of the cal-
culated solvation free energies, partly explaining why the
predominant-states approximation did not signiﬁcantly
improve upon the single- and two-state approximations.
As an additional consideration, we analyzed the struc-
tural differences of the global minimum conformations in
membrane and in water and estimated DGH2O [13], deﬁned
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123as the difference in free energy between the global mini-
mum conformation in water, xH2O, and the global minimum
conformation in chloroform, xCHCl3, each evaluated in
water, which measures the reorganizational free energy
upon solvent transfer, i.e.,
DGH2O ¼ U xH2O ðÞ þ WH2O xH2O ðÞ   U xCHCl3 ðÞ
  WH2O xCHCl3 ðÞ ð 8Þ
Global minimum conformations for representative
compounds are shown in Fig. 4 while the heavy-atom
and polar-hydrogen atom RMSD separating the global
minima, along with the DGH2O values are reported in
Table 1. Most of the RMSD values are under 2 A ˚,
indicating a high degree of similarity in chloroform and
water, which agrees with the images presented in Fig. 4.
This is consistent with the DGH2O values that are all nearly
less than RT at 310 K, indicating that in water, the
conformation at the global minimum in chloroform is
frequently visited. The notable exception is verapamil,
which is also the largest outlier in the single-state
Table 1 Conformational effects on solvent transfer on the FDA set
Compound %G of global minimum, H2O
a %G of global minimum, CHCl3
a RMSD (A ˚)
b DGwat(kcal mol
-1)
c
Alfentanil 99.0/99.9 99.2/99.9 2.24 -0.21
Alprenol 98.5/99.8 98.6/99.7 1.85 -0.80
Atenolol 97.5/99.8 98.5/99.7 0.91 -0.24
Cimetidine 96.0/99.4 99.0/99.7 2.37 -0.83
Diltiazem 98.0/99.9 99.0/99.9 0.05 -0.23
Metoprolol 98.0/99.8 97.8/99.8 1.76 -0.52
Nadolol 98.6/99.9 99.0/99.8 0.64 -0.24
Pindolol 98.5/99.8 99.0/99.8 1.41 -0.44
Propranolol 99.0/99.9 99.0/99.9 0.82 -0.14
Terbutaline 98.0/99.8 98.5/99.8 1.11 -0.33
Verapamil 99.0/99.7 99.0/99.7 1.80 -2.75
a The number on the left of the ‘‘/’’ is the percentage of the free energy in the indicated solvent attributable to the just the global minimum. The
number on the right of the ‘‘/’’ is the percentage attributable to all conformer that are within 1.00 kcal mol
-1 of the global minimum
b The RMSD is measured between the global minimum in implicit water and chloroform
c Deﬁned in Eq. 8
water chloroform
Alfentanil a
water chloroform
Verapamil
b
Fig. 4 Global minima in
chloroform and water for
representative compounds from
the FDA set, a alfentanil,
b verapamil
J Comput Aided Mol Des (2011) 25:1007–1017 1013
123approximation (Fig. 3a). Based on the barrier domain
model, the slightly better performance of the single-state
model implies that the conformations found at the global
minimum in implicit chloroform may better represent the
dominant conformations found at the membrane-water
interface. In contrast, the fact that verapamil is the largest
outlier and has the largest DGH2O value may indicate that
its dominant membrane-water interface conformation is
more similar to the global minimum in bulk water.
The congeneric set
The logarithm of the experimentally determined perme-
abilities are plotted against the corresponding DG values
determined using the single-, two- and predominate-states
approximations (Fig. 5a, b and c, respectively). The QSPR
results are shown in Fig. 4d. The single-state approxima-
tion gives an R
2 of 0.72, the two-state approximation an R
2
of 0.72, the predominant-states approximation an R
2 of
0.71, and the QSPR method predictions have an R
2 of 0.58.
The single- and two-state approximations performed
identically. The matching performance is attributable to the
small number of rotamers in the congeneric set, which
results in a very small conformational ensemble and vir-
tually identical global minimum conformations in each
solvent. DGwat and heavy atom RMSD values (Table 2)
support this claim. The absolute value of DGwat doesn’t
exceed 0.16 kcal mol
-1 and all of the RMSD values are
below 0.38 A ˚, with most falling below 0.01 A ˚, conﬁrming
the near conformational parity of the global minima in each
solvent.
The small conformational ensemble also explains the
performance of the predominant-states approximation,
which was nearly equivalent to the single-state and two-
state approximations. When there are a substantial number
of conformations that contribute to the conﬁguration inte-
gral, the free energies estimated using the predominant-
states approximation will be different than those estimated
using only the global minimum. However, as compounds in
the congeneric set have few rotamers, the number of con-
formations is limited. For example, we found two phenol
conformations in both chloroform and water, while for
BPMC, the most ﬂexible of the set, 41 conformations were
found in chloroform and 44 in water. This is signiﬁcantly
fewer than the hundreds to thousands of conformers found
for compounds in the FDA set. As a result, the three
approximations yield similar estimates, explaining why all
three give permeabilities that correlate nearly identically
with experiment.
None of the approximations show particular sensitivity
to the small structural differences present in the congeneric
set. Rather, with the exception of the two-state approxi-
mation, performance is slightly worse on this set than the
structurally more diverse FDA set. Nevertheless, all three
approximations outperform the QSPR model, which seems
unable to effectively separate the permeabilities of the
structural homologs (note the mass of data points on the
upper right hand side of the curve in Fig 5d). Assuming the
relative performance extends beyond the simple series
examined here, each of the approximations may be better at
teasing apart the subtle structural inﬂuences on perme-
ability than an all-purpose QSPR method. In particular,
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Fig. 5 Correlation with
experiment for compounds in
the congeneric set, a the single
state approximation R
2 = 0.72,
b the two-state approximation,
R
2 = 0.72, c the predominant-
states approximation R
2 = 0.71,
d QSPR R
2 = 0.58
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123when the number of rotamers is small, the approximations
perform nearly identically, and as the single-state approx-
imation is the least computationally intensive, it is the most
appropriate choice.
Conclusions
This work expanded upon earlier work by the Jacobson
group [11, 13] and addressed the effects of conformational
sampling on permeability predictions based on the
homogenous solubility model of passive membrane per-
meability. By invoking the barrier domain model [12],
which posits that permeation is limited by passage through
a single ‘‘barrier domain’’ and assumes diffusivity differ-
ences are small, the model determines permeability as a
function of the free energy change of barrier crossing. The
barrier domain is generally taken as the ordered, apolar
region behind the head groups [8, 9, 12], and in this work,
as in the work reported by the Jacobson group, the free
energy barrier is estimated as the difference in chloroform
and aqueous solvation free energies. A statistical thermo-
dynamic description of the solvation free energy difference
was developed and three limiting assumptions, differing in
the extent of solute conformational sampling, were made to
evaluate the conﬁguration integrals. The single-state
approximation, which is identical to the approximation
used by the Jacobson group [11, 13], is based on the
assumption that the global minimum conformation in
chloroform dominates both integrals. The two-state
approximation is based on the assumption that the global
minimum in each solvent dominates their respective inte-
grals. Finally, the predominant-states approximation
decomposes each conﬁguration integral into a sum of
conﬁguration integrals, each of which are centered on
conformers determined in a conformational search, that are
evaluated by Monte Carlo importance sampling. We tested
each approximation on a set of eleven structurally diverse
FDA approved compounds, as well as a set of thirteen
simple benzene congeners intended to mimic the subtle
changes that might be proposed during lead optimization.
Moreover, to compare the performance of each approxi-
mation to a QSPR model, permeabilities for both sets were
computed with QikProp, a fast, knowledge-based phar-
macokinetic property predictor available from Schro ¨dinger.
Our principal ﬁnding was that more rigorous treatments
of the conformational distributions of the solute do not
improve correlation with experiment. We attribute this to
the solvation free energy landscape, which for all com-
pounds in both chloroform and water is dominated by the
global minimum. Moreover, as the number of rotameric
states decreases, the size of the conformational ensemble is
reduced and discrepancy between the three approximations
is diminished. Whether or not other small molecules
behave similarly will need to be addressed on a case-by-
case basis. Between the two-state and single-state
approximation, the single-state approximation is likely the
most robust, slightly outperforming the other two approx-
imations on the FDA set, and performing as well as the
two-state approximation on the congeneric set. While the
QSPR model performed as well as the single-state model
for the structurally diverse FDA set, it was unable to
effectively separate the permeabilities of the congeneric
set. Assuming the performances extend beyond the com-
pound sets we’ve tested here, the computationally inex-
pensive QSPR methods are best applied as ﬁlters for large
sets of structurally diverse compounds when establishing a
docking library, while the more expensive single-state
approximation may be suited to a lead-optimization setting.
Considering both the FDA and congeneric sets, coefﬁ-
cients of determination (R
2) values were never better than
0.75, so while the estimated solvation free energies capture
most of the permeability variation, some is lost, which may
be attributable to one or more causes. First, it may indicate
that the barrier domain model is an inappropriate descrip-
tion of membrane permeability. Structural anisotropy in the
membrane is widely accepted, and it has been shown that
both the free energy of solvating a compound in the
membrane, as well as a compound’s intramembrane dif-
fusion coefﬁcient, depend on the depth of the compound in
the membrane [8, 9]. As permeability is, in fact, due to
passage across the entire membrane, and not just the rate
limiting region, or ‘‘barrier-domain,’’ the barrier domain
model falls short of a complete physical description of the
Table 2 Conformation effects on solvent transfer on the congeneric
set
Compound RMSD (A ˚)
a DGwat (kcal mol
-1)
b
Phenol 0.001 -0.09
2-methylphenol 0.002 -0.04
2,4-dimethylphenol 0.002 -0.04
2-chlorophenol 0.100 -0.05
2,4-dichlorophenol 0.080 -0.06
4-cyanophenol 0.002 -0.05
Hydroxyquinone 0.002 -0.03
Acetaminophine 0.375 -0.10
Aniline 0.002 -0.12
2-chloroaniline 0.002 -0.12
3-chloroaniline 0.002 -0.16
4-chloroaniline 0.002 -0.15
BPMC 0.005 -0.04
a The RMSD is measured between the global minimum in implicit
water and chloroform
b Deﬁned in Eq. 8
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123process, possibly leading to erroneous estimates. Alterna-
tively, the barrier domain model may adequately describe
the fundamental quantities that affect membrane perme-
ability, but errors in our calculations are causing the dis-
crepancies with experiment. As generalized Born solvent
models estimate results of the theoretically more rigorous
Poisson-Boltzmann equation [28], which itself is a mean
ﬁeld approximation of the exact case, some of the calcu-
lations presented here may very well be erroneous.
Unfortunately, as chloroform-water partition coefﬁcients
for the tested compounds have not been published, accurate
calculations cannot currently be separated from inaccurate
calculations. Nevertheless, the rapid GBSA implicit sol-
vent models of water and chloroform require less compu-
tational effort than the more detailed all-atom models while
still capturing the general dielectric character of the
aqueous and membrane phases. A third alternative is that
the compounds examined diffuse very differently through
the membrane, invalidating our assumption that diffusion
can be neglected. While any of these possibilities may
explain why better correlation with experiment was not
obtained, all three likely contribute to a greater or lesser
extent depending upon the compound set of interest.
Finally, while the models we tested here can provide
reasonable correlation with experiment, their robustness
needs to be explored across much larger compound sets.
However, as many drug-like molecules are acidic or basic,
a robust means of treating titratable compounds ﬁrst needs
to be established.
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